|
業務類別
|
Drug Manufacturers - General |
|
業務概覽
|
Gilead Sciences develops and markets therapies to treat and prevent life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. Gilead's acquisition of Pharmasset brought rights to hepatitis Cdrug Sovaldi, which is also part of newer combination regimens that remain standards of care. Gilead is also growing its presence in the oncology market via acquisitions, led by CAR-T cell therapy Yescarta/Tecartus (from Kite) and breast and bladder cancer therapy Trodelvy (from Immunomedics). |
| 公司地址
| 333 Lakeside Drive, Foster City, CA, USA, 94404 |
| 電話號碼
| +1 650 574-3000 |
| 傳真號碼
| +1 650 522-5853 |
| 公司網頁
| https://www.gilead.com |
| 員工數量
| 17000 |
| Mr. Andrew D. Dickinson |
Chief Financial Officer |
美元 1.08M |
24/02/2026 |
| Ms. Erin Burkhart |
Senior Vice President, Controllership and Principal Accounting Officer |
-- |
24/02/2026 |
| Mr. Daniel P. O'Day |
Chairman of the Board and Chief Executive Officer |
美元 1.77M |
24/02/2026 |
| Dr. Dietmar Berger, M.D.,PhD |
Chief Medical Officer |
-- |
24/02/2026 |
| Ms. Keeley M. Cain Wettan |
Executive Vice President, Legal and Compliance and General Counsel |
-- |
24/02/2026 |
| Ms. Johanna Mercier |
Chief Commercial and Corporate Affairs Officer |
美元 1.15M |
24/02/2026 |
|
|
| Mr. Anthony Welters |
Lead Independent Director |
24/02/2026 |
| Dr. Jacqueline K. Barton, PhD |
Independent Director |
24/02/2026 |
| Mr. Javier J. Rodriguez |
Independent Director |
24/02/2026 |
| Mr. Harish Manwani |
Independent Director |
24/02/2026 |
| Mr. Daniel P. O'Day |
Chairman of the Board and Chief Executive Officer |
24/02/2026 |
| Dr. Ted W. Love, M.D. |
Independent Director |
24/02/2026 |
| Ms. Kelly Anne Kramer |
Independent Director |
24/02/2026 |
| Dr. Sandra J. Horning, M.D. |
Independent Director |
24/02/2026 |
| Dr. Jeffrey A. Bluestone, PhD |
Independent Director |
24/02/2026 |
|
|
|
|
